Rationale for contemporary antimicrobial treatment of Stenotrophomonas maltophilia: a narrative review

Simple item page
dc.contributor.authorTurnidge, J.
dc.contributor.authorGatermann, S.
dc.contributor.authorKahlmeter, G.
dc.contributor.authorCantón, R.
dc.contributor.authorWootton, M.
dc.contributor.authorGiske, C.G.
dc.date.issued2025
dc.description.abstractBackground: Stenotrophomonas maltophilia is an opportunistic pathogen most commonly isolated from patients with complex/life-threatening disease or cystic fibrosis. Traditionally, when treatment is warranted, trimethoprim-sulfamethoxazole has been the agent of choice, alone or in combination with a fluoroquinolone or tetracycline. Objectives: This narrative review aims to provide the latest information on the role of different antimicrobial agents or combinations of agents in treating S. maltophilia infections and offer the rationale for interpretive criteria revised by EUCAST in 2025. Sources: We searched PubMed to identify literature about the pharmacodynamics and clinical efficacy of a range of current and proposed antimicrobial agents and their combinations. Content: Recent in vitro and animal studies have provided insights into the pharmacodynamics of a range of antimicrobial agents previously or currently considered effective in treating S. maltophilia infections. These studies challenge the view that trimethoprim-sulfamethoxazole should be the agent of choice. In reviewing the recent literature, we attempted to answer the following questions: (1) Is the pharmacodynamic evidence about trimethoprim-sulfamethoxazole sufficient to suggest that it should be replaced as the first choice for therapy? (2) Do the pharmacodynamic studies on other agents provide information about appropriateness of currently recommended dosages? (3) Is there clinical evidence to support the choice of one or another therapeutic strategy, and (4) Are combinations of agents with or without trimethoprim-sulfamethoxazole superior to monotherapy? Implications: Based on the assessment of the data, EUCAST found cefiderocol a potential alternative to trimethoprim-sulfamethoxazole, although the clinical evidence is still too limited to allow a clinical breakpoint. The other antimicrobial agents have limitations in their activity, as assessed by PK/PD data, but might have a role in combination therapy. However, no data were found to convincingly support the superiority of combination therapy over monotherapy.
dc.description.statementofresponsibilityJohn Turnidge, Sören Gatermann, Gunnar Kahlmeter, Rafael Cantón, Mandy Wootton, Christian G. Giske, on behalf of the European Committee on Antimicrobial Susceptibility Testing
dc.identifier.citationCMI Communications, 2025; 2(2):105082-1-105082-6
dc.identifier.doi10.1016/j.cmicom.2025.105082
dc.identifier.issn2950-5909
dc.identifier.issn2950-5909
dc.identifier.orcidTurnidge, J. [0000-0003-4240-5578]
dc.identifier.urihttps://hdl.handle.net/2440/147020
dc.language.isoen
dc.publisherElsevier BV
dc.rights© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
dc.source.urihttps://doi.org/10.1016/j.cmicom.2025.105082
dc.subjectStenotrophomonas maltophilia; Treatment; Trimethoprim-sulfamethoxazole; Cefiderocol; Pharmacokinetic; Pharmacodynamic; Colonization
dc.titleRationale for contemporary antimicrobial treatment of Stenotrophomonas maltophilia: a narrative review
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_147020.pdf
Size:
353.2 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Research Outputs